TPI Composites files for Chapter 11 bankruptcy, plans delisting from Nasdaq
Xiao Ting, a director at Zenas BioPharma, Inc. (NASDAQ:ZBIO), has acquired 10,000 shares of the company’s common stock, according to a recent filing with the Securities and Exchange Commission. The transaction, dated February 7, 2025, was executed at a weighted average price of $7.76 per share, resulting in a total purchase value of $77,600. This acquisition increases Ting’s total holdings to 47,000 shares. The purchase comes as the stock has fallen nearly 60% over the past six months, according to InvestingPro data.
The shares were bought in multiple transactions with prices ranging from $7.64 to $7.78, as noted in the filing. This purchase reflects Ting’s continued investment in the pharmaceutical company, which is headquartered in Waltham, Massachusetts. With a market capitalization of $316 million, Zenas maintains a strong liquidity position with a current ratio of 8.95. The company is scheduled to report earnings on February 26, 2025. InvestingPro subscribers can access 8 additional key insights about ZBIO’s financial health and growth prospects.
In other recent news, H.C. Wainwright has initiated coverage on Zenas Biopharma with a Buy rating, focusing on the potential of its lead autoimmune therapy, obexelimab. The firm underscored obexelimab’s innovative approach to treating chronic autoimmune diseases, which distinguishes it from existing B cell therapies. Obexelimab targets B cells more broadly, potentially maintaining low B cell numbers and activity without long-term depletion.
Similarly, Guggenheim reiterated its Buy rating on Zenas Biopharma, expressing confidence in obexelimab’s unique mechanism of action and its potential across multiple indications. The firm highlighted the convenience of obexelimab’s once-weekly subcutaneous administration and its potential superiority to anti-CD20 treatments in Relapsing Multiple Sclerosis based on preclinical models.
H.C. Wainwright and Guggenheim both pointed out key clinical milestones for Zenas Biopharma. These include the expected results from the Phase 3 INDIGO trial for IgG4-RD at the end of 2025, the primary endpoint 12-week data from the Phase 2 MoonStone trial for RMS in the third quarter of 2025, and the primary endpoint 24-week data from the Phase 2 SunStone trial for SLE in the first half of 2026. These developments represent recent advancements in Zenas Biopharma’s immunology pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.